125 related articles for article (PubMed ID: 38185453)
1. European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice: Data from the Fight Retinal Blindness! Registry.
Boudousq C; Nguyen V; Hunt A; Gillies M; Zarranz-Ventura J; O'Toole L; Mangelschots E; Kusenda P; Schmidt-Erfurdt U; Pollreisz A; Kheir WJ; Arruabarrena C; Vujosevic S; Barthelmes D; Creuzot-Garcher C; Gabrielle PH
Ophthalmol Retina; 2024 Jun; 8(6):527-536. PubMed ID: 38185453
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
Nguyen CL; Gillies MC; Nguyen V; Daien V; Cohn A; Banerjee G; Arnold J;
Ophthalmology; 2019 May; 126(5):735-742. PubMed ID: 30529685
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands.
Verbraak FD; Ponsioen DL; Tigchelaar-Besling OAM; Nguyen V; Gillies MC; Barthelmes D; Klaver CCW
Acta Ophthalmol; 2021 Sep; 99(6):e884-e892. PubMed ID: 33354933
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
[TBL] [Abstract][Full Text] [Related]
5. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
[TBL] [Abstract][Full Text] [Related]
6. Twelve-month outcomes of intra-vitreal anti-VEGF agents for treatment-naïve neovascular age-related macular degeneration eyes: French data from the fight for retinal blindness!
Lestable L; Gabrielle PH; Bron AM; Nguyen P; Creuzot-Garcher C
J Fr Ophtalmol; 2020 Oct; 43(8):761-769. PubMed ID: 32622633
[TBL] [Abstract][Full Text] [Related]
7. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab.
Raimondi R; Falfeli T; Bogdanova-Bennet A; Varma D; Habib M; Kotagiri A; Steel DH; Grinton M
Ophthalmol Retina; 2024 Jun; 8(6):537-544. PubMed ID: 38040055
[TBL] [Abstract][Full Text] [Related]
9. FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fight Retinal Blindness! Project.
Cornish EE; Teo KY; Nguyen V; Squirrel D; Young S; Gillies MC; Barthelmes D
Retina; 2021 Jan; 41(1):118-124. PubMed ID: 32310628
[TBL] [Abstract][Full Text] [Related]
10. Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-vascular endothelial growth factor therapy using SSOCTA.
Told R; Reiter GS; Mittermüller TJ; Schranz M; Reumueller A; Schlanitz FG; Weigert G; Pollreisz A; Sacu S; Schmidt-Erfurth U
Acta Ophthalmol; 2021 Mar; 99(2):e240-e246. PubMed ID: 32706171
[TBL] [Abstract][Full Text] [Related]
11. A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013-2016. The Fight Retinal Blindness! Project.
Barthelmes D; Nguyen V; Walton R; Gillies MC; Daien V;
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1839-1846. PubMed ID: 30051312
[TBL] [Abstract][Full Text] [Related]
12. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P
Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
[TBL] [Abstract][Full Text] [Related]
13. Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents.
Evans RN; Reeves BC; Maguire MG; Martin DF; Muldrew A; Peto T; Rogers C; Chakravarthy U
JAMA Ophthalmol; 2020 Oct; 138(10):1043-1051. PubMed ID: 32816002
[TBL] [Abstract][Full Text] [Related]
14. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration.
Essex RW; Nguyen V; Walton R; Arnold JJ; McAllister IL; Guymer RH; Morlet N; Young S; Barthelmes D; Gillies MC;
Ophthalmology; 2016 Nov; 123(11):2393-2400. PubMed ID: 27554034
[TBL] [Abstract][Full Text] [Related]
17. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.
Arnold JJ; Campain A; Barthelmes D; Simpson JM; Guymer RH; Hunyor AP; McAllister IL; Essex RW; Morlet N; Gillies MC;
Ophthalmology; 2015 Jun; 122(6):1212-9. PubMed ID: 25846847
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Creuzot-Garcher C; Miguel L; Alforja S; Sararols L; Casaroli-Marano RP; Zarranz-Ventura J; Gillies M; Arnold J; Barthelmes D
Acta Ophthalmol; 2022 Feb; 100(1):e288-e296. PubMed ID: 33960115
[TBL] [Abstract][Full Text] [Related]
19. Improved Structure and Function in Early-Detected Second-Eye Neovascular Age-Related Macular Degeneration: FASBAT/Early Detection of Neovascular Age-Related Macular Degeneration Report 1.
Gale RP; Airody A; Sivaprasad S; Hanson RLW; Allgar V; McKibbin M; Morland AB; Peto T; Porteous M; Chakravarthy U;
Ophthalmol Retina; 2024 Jun; 8(6):545-552. PubMed ID: 38171416
[TBL] [Abstract][Full Text] [Related]
20. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
